Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Azitra, Inc. (AZTR)

Azitra Advances ATR-04 Trial to Cohort 2 After Safety Review Committee Clearance

Neutral Impact 3 of 5 other Written later

Azitra said its safety review committee recommended that the Phase 1/2 trial of ATR04-484 for EGFR inhibitor-associated skin rash may proceed to Cohort 2, allowing enrollment and dosing to begin in that cohort. The filing contains no financial results, and the update concerns clinical progress only, based on a safety review of six patients from Cohort 1.

Key points

  • Safety review committee recommended proceeding to Cohort 2 after reviewing safety data from six patients in Cohort 1 (seven patients received a single 4g application).
  • Cohort 2 is expected to enroll approximately 24 patients receiving a 4g application once daily for 28 days.
  • The study is being conducted at six clinical sites, including MD Anderson Cancer Center and Yale University.
  • The FDA has granted Fast Track designation to ATR04-484 for EGFR inhibitor-associated rash, which affects approximately 150,000 patients annually in the United States.

The filing

CompanyAzitra, Inc. (AZTR)
Form8-K, current report
Filed with the SECOct 1, 2026, 8:10 AM ET
Accession number0001493152-26-045260

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.